EYPT

SEC source: 0001562180-19-003665 · primarydocument.xml · derivative · entry 1

Godshall Douglas Evan · CIK 0001404227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2029-02-21

SEC source: 0001562180-19-003669 · primarydocument.xml · derivative · entry 1

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2020-06-25

F1 · derivative.exercise_price: Reflects the closing price of the Company's common stock on February 21, 2019, which was the date the option grant was approved by the Compensation Committee of the Board of Directors (the "Committee") of EyePoint Pharmaceuticals, Inc. (the "Registrant"), subject to stockholder approval of an amendment to the Registrant's 2016 Long Term Incentive Plan (the "Plan Amendment").

F2 · date: The option grant was approved by the Committee on February 21, 2019, subject to stockholder approval of the Plan Amendment. The Registrant's stockholders approved the Plan Amendment on June 25, 2019.

F3 · derivative.exercise_date: The option to purchase, which vested immediately upon Mr. Rogers' departure from the Board, will be exercisable until June 25, 2020

F3 · derivative.expiration_date: The option to purchase, which vested immediately upon Mr. Rogers' departure from the Board, will be exercisable until June 25, 2020

SEC source: 0001562180-19-003668 · primarydocument.xml · derivative · entry 1

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2029-02-21

SEC source: 0001562180-19-003667 · primarydocument.xml · derivative · entry 1

Duker Jay S. · CIK 0001630864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2029-02-21

SEC source: 0001562180-19-003660 · primarydocument.xml · derivative · entry 1

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 370,000

Underlying: Common Stock · 370,000 shares

Expires 2029-02-21

F1 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 21, 2019

SEC source: 0001562180-19-003628 · primarydocument.xml · derivative · entry 2

Peterson Kristine · CIK 0001508596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.exercise_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.expiration_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0001562180-19-003628 · primarydocument.xml · nonDerivative · entry 1

Peterson Kristine · CIK 0001508596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

SEC source: 0001562180-19-003627 · primarydocument.xml · derivative · entry 2

Godshall Douglas Evan · CIK 0001404227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.exercise_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.expiration_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0001562180-19-003627 · primarydocument.xml · nonDerivative · entry 1

Godshall Douglas Evan · CIK 0001404227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,167

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

SEC source: 0001562180-19-003630 · primarydocument.xml · derivative · entry 2

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.exercise_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.expiration_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0001562180-19-003630 · primarydocument.xml · nonDerivative · entry 1

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,167

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

SEC source: 0001562180-19-003629 · primarydocument.xml · derivative · entry 2

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On June 21, 2018, the reporting person was granted 8,333 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.exercise_date: On June 21, 2018, the reporting person was granted 8,333 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.expiration_date: On June 21, 2018, the reporting person was granted 8,333 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0001562180-19-003629 · primarydocument.xml · nonDerivative · entry 1

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

SEC source: 0001562180-19-003626 · primarydocument.xml · derivative · entry 2

Duker Jay S. · CIK 0001630864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.exercise_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F2 · derivative.expiration_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0001562180-19-003626 · primarydocument.xml · nonDerivative · entry 1

Duker Jay S. · CIK 0001630864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,167

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

SEC source: 0001562180-19-003561 · primarydocument.xml · derivative · entry 3

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,560

Underlying: Common Stock · 8,280 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: On June 14, 2018, the reporting person was granted 24,840 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

F3 · derivative.expiration_date: On June 14, 2018, the reporting person was granted 24,840 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0001562180-19-003561 · primarydocument.xml · nonDerivative · entry 2

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,338

F2 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units

SEC source: 0001562180-19-003561 · primarydocument.xml · nonDerivative · entry 1

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,732

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001562180-19-003562 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 45,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: On June 14, 2018, the reporting person was granted 135,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

F2 · derivative.expiration_date: On June 14, 2018, the reporting person was granted 135,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0001562180-19-003562 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 285,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001562180-19-003560 · primarydocument.xml · derivative · entry 3

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,400

Underlying: Common Stock · 14,200 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: On June 14, 2018, the reporting person was granted 42,600 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

F3 · derivative.expiration_date: On June 14, 2018, the reporting person was granted 42,600 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0001562180-19-003560 · primarydocument.xml · nonDerivative · entry 2

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,437

F2 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units

SEC source: 0001562180-19-003560 · primarydocument.xml · nonDerivative · entry 1

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,612

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001562180-19-003509 · primarydocument.xml · derivative · entry 1

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2029-06-10

F1 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at June 10th, 2020 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-19-002822 · primarydocument.xml · nonDerivative · entry 1

Landis John B. · CIK 0001477283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

SEC source: 0001562180-19-002284 · primarydocument.xml · derivative · entry 2

Duker Jay S. · CIK 0001630864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2027-06-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-002284 · primarydocument.xml · nonDerivative · entry 1

Duker Jay S. · CIK 0001630864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-002080 · primarydocument.xml · derivative · entry 2

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2019-06-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option was granted on 6/25/2009 and vested in four equal annual installments beginning on the first anniversary of the grant.

SEC source: 0001562180-19-002080 · primarydocument.xml · nonDerivative · entry 1

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,452

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-002168 · primarydocument.xml · nonDerivative · entry 1

Duker Jay S. · CIK 0001630864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

SEC source: 0001562180-19-002055 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,200

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.74 to $1.81. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-19-002053 · primarydocument.xml · nonDerivative · entry 1

Godshall Douglas Evan · CIK 0001404227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,500

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.75 to $1.77. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-19-002054 · primarydocument.xml · derivative · entry 2

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2027-06-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-002054 · primarydocument.xml · nonDerivative · entry 1

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-002006 · primarydocument.xml · nonDerivative · entry 1

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,452

F1 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units

F2 · price: Reflects the last reported sale price for the Registrant's shares of common stock on the Nasdaq Global Market on March 19, 2019

SEC source: 0001562180-19-002007 · primarydocument.xml · nonDerivative · entry 1

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,412

F1 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units

F2 · price: Reflects the last reported sale price for the Registrant's shares of common stock on the Nasdaq Global Market on March 19, 2019

SEC source: 0001562180-19-000563 · primarydocument.xml · derivative · entry 1

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2029-01-25

F1 · derivative.exercise_date: The option becomes exercisable in three equal annual installments beginning on January 25, 2020.

SEC source: 0000899243-18-031698 · doc4.xml · derivative · entry 3

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 62,892 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: On December 22, 2017, the reporting person was granted 62,892 restricted stock units, vesting in full on the first anniversary of the grant date.

F4 · derivative.expiration_date: On December 22, 2017, the reporting person was granted 62,892 restricted stock units, vesting in full on the first anniversary of the grant date.

SEC source: 0000899243-18-031698 · doc4.xml · nonDerivative · entry 2

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,187

F2 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.

F3 · price: Reflects the last reported sale price for the Registrant's shares of common stock on the Nasdaq Global Market on December 21, 2018.

SEC source: 0000899243-18-031698 · doc4.xml · nonDerivative · entry 1

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,709

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000899243-18-029124 · doc4.xml · derivative · entry 2

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires 2018-11-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-18-029124 · doc4.xml · nonDerivative · entry 1

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Consists of (i) 100,000 shares of common stock, par value $0.001 per share, of EyePoint Pharmaceuticals, Inc. (the "Company") acquired upon exercise of the stock option as described above and (ii) 12,500 shares of common stock of the Company underlying certain deferred stock units ("DSUs") previously awarded to the reporting person, with each DSU representing the right to receive one share of common stock of the Company. These DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986,

SEC source: 0000899243-18-027573 · doc4.xml · derivative · entry 1

Landis John B. · CIK 0001477283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2028-10-25

F1 · derivative.exercise_date: The option becomes exercisable in three equal annual installments beginning on October 25, 2019.

SEC source: 0000899243-18-026782 · doc4.xml · nonDerivative · entry 2

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,817

F2 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the performance stock units.

SEC source: 0000899243-18-026782 · doc4.xml · nonDerivative · entry 1

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,762

F1 · shares: On October 12, 2018 (the "FDA Approval Date"), the U.S. Food and Drug Administration approved EyePoint Pharmaceutical Inc.'s (the "Company") new drug application for YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. As a result, 10,000 shares representing a previously granted performance stock unit award vested on that date. An additional 10,000 shares from this award will vest on the first anniversary of the FDA Approval Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.

SEC source: 0000899243-18-026783 · doc4.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 211,700

F1 · shares: On October 12, 2018 (the "FDA Approval Date"), the U.S. Food and Drug Administration approved EyePoint Pharmaceutical Inc.'s (the "Company") new drug application for YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. As a result, 38,334 shares representing a previously granted performance stock unit award vested on that date. An additional 38,333 shares from this award will vest on the first anniversary of the FDA Approval Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.

SEC source: 0000899243-18-026781 · doc4.xml · nonDerivative · entry 2

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,600

F2 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the performance stock units.

SEC source: 0000899243-18-026781 · doc4.xml · nonDerivative · entry 1

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,055

F1 · shares: On October 12, 2018 (the "FDA Approval Date"), the U.S. Food and Drug Administration approved EyePoint Pharmaceutical Inc.'s (the "Company") new drug application for YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. As a result, 8,334 shares representing a previously granted performance stock unit award vested on that date. An additional 8,333 shares from this award will vest on the first anniversary of the FDA Approval Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.

SEC source: 0000899243-18-026697 · doc4.xml · derivative · entry 1

ANDO GORAN · CIK 0001110748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2028-10-11

F1 · derivative.exercise_date: The option becomes exercisable in three equal annual installments beginning on October 11, 2019.

SEC source: 0000899243-19-003415 · doc5.xml · nonDerivative · entry 2

EW Healthcare Partners, L.P. · CIK 0001612343 · 10% owner

EW Healthcare Partners-A, L.P. · CIK 0001736240 · 10% owner

Essex Woodlands Fund IX-GP, L.P. · CIK 0001652285 · 10% owner

Essex Woodlands IX, LLC · CIK 0001652286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · EW Healthcare Partners-A L.P.

Disclosed balance after: 41,903,956

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 40,283,255 shares held by EW Healthcare Partners L.P. ("EWHP") and 1,620,701 shares held by EW Healthcare Partners-A L.P. ("EWHP-A"). Essex Woodlands Fund IX-GP, L.P. ("Fund IX-GP") is the general partner of EWHP and EWHP-A, respectively. Essex Woodlands IX, LLC (the "General Partner") is the general partner of Fund IX-GP. The General Partner holds sole voting and dispositive power over the shares held by EWHP and EWHP-A. The managers of the General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman (also a member of the Issuer's board of directors) and Petri Vainio (collectively, the "Managers"), and may exercise voting and investment control over the shares only by the majority action of the Managers.

F1 · ownership.direct: Includes 40,283,255 shares held by EW Healthcare Partners L.P. ("EWHP") and 1,620,701 shares held by EW Healthcare Partners-A L.P. ("EWHP-A"). Essex Woodlands Fund IX-GP, L.P. ("Fund IX-GP") is the general partner of EWHP and EWHP-A, respectively. Essex Woodlands IX, LLC (the "General Partner") is the general partner of Fund IX-GP. The General Partner holds sole voting and dispositive power over the shares held by EWHP and EWHP-A. The managers of the General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman (also a member of the Issuer's board of directors) and Petri Vainio (collectively, the "Managers"), and may exercise voting and investment control over the shares only by the majority action of the Managers.